These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30732170)

  • 1. Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes.
    Sr K; G B; Jain S; Moorthy N; Manjunath SC; Christopher R
    Medicine (Baltimore); 2019 Feb; 98(6):e14365. PubMed ID: 30732170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
    Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
    Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
    Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
    Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
    Kalpana SR; Bharath G; Manjunath CN; Christopher R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
    Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
    Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.
    Kim KA; Song WG; Lee HM; Joo HJ; Park JY
    Mol Biol Rep; 2014 Nov; 41(11):7305-12. PubMed ID: 25069408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.
    Li B; Liu R; Wang C; Ren C; Zhang S; Zhang F; Zhang J; Liu S; Wei Y; Liu W; Song B; Wu X
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1685-1693. PubMed ID: 31444512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
    Giraldo-Ocampo S; Diaz-Ordoñez L; Silva-Cuero YK; Gutierrez-Medina JD; Candelo E; Diaz JA; Pachajoa H
    Medicine (Baltimore); 2023 Jul; 102(30):e34204. PubMed ID: 37505171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
    Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
    Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
    Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery.
    Tatarunas V; Lesauskaite V; Veikutiene A; Grybauskas P; Jakuska P; Jankauskiene L; Bartuseviciute R; Benetis R
    J Thromb Thrombolysis; 2014; 37(2):177-85. PubMed ID: 23677510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
    Sridharan K; Sivaramakrishnan G
    J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
    Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
    Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.